Achieving ventricular rate control in patients taking chronic beta-blocker therapy

Megan E. Feeney, Sandra L.B. Rowe, Nathan D. Mah, Cassie A. Barton, Ran Ran

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Study Objective. The objective of this study is to evaluate the difference in response to ventricular rate control with intravenous (IV) metoprolol compared to IV diltiazem in patients taking chronic beta-blocker therapy who present to the emergency department (ED) in atrial fibrillation (AF) with rapid ventricular rate (RVR). Methods This was a single-center, retrospective study of adult patients taking chronic oral metoprolol. Chronic metoprolol therapy was defined as patients prescribed and taking oral metoprolol within 5 days of study inclusion. Rate control was defined as either a decrease in ventricular rate < 100 bpm or < 120 bpm if the decrease was at least 20% from the presenting heart rate. Results A total of 332 patients were included, with 16 patients in the IV diltiazem group and 316 patients in the IV metoprolol group. In the diltiazem arm, 68.8% of patients achieved successful rate control compared to 42.4% of patients in the metoprolol group (p = 0.067). Treatment with IV metoprolol resulted in more hospital admissions (58% vs. 6.25% with diltiazem, p < 0.001). Treatment with diltiazem was associated with a greater incidence of bradycardia compared to IV metoprolol (13% vs. 0%, p = 0.002). Conclusions The use of IV diltiazem was associated with a higher rate of successful response to rate control compared to IV metoprolol in patients in AF with RVR on chronic beta-blocker therapy, however the difference between groups was not statistically significant.

Original languageEnglish (US)
Pages (from-to)110-113
Number of pages4
JournalAmerican Journal of Emergency Medicine
Issue number1
StatePublished - Jan 2018


  • Atrial fibrillation
  • Beta-blocker
  • Calcium channel blocker
  • Diltiazem
  • Metoprolol

ASJC Scopus subject areas

  • Emergency Medicine


Dive into the research topics of 'Achieving ventricular rate control in patients taking chronic beta-blocker therapy'. Together they form a unique fingerprint.

Cite this